www.impactjournals.com/oncotarget/ Oncotarget, Advance Publications 2017 Epigenomic study identifies a novel mesenchyme homeobox2- GLI1 transcription axis involved in cancer drug resistance, overall survival and therapy prognosis in lung cancer patients Armas López Leonel1, Piña-Sánchez Patricia2, Arrieta Oscar3, Guzman de Alba Enrique4, Ortiz Quintero Blanca4, Santillán Doherty Patricio4, Christiani David C.5, Zúñiga Joaquín4 and Ávila-Moreno Federico1,4 1National University Autonomous of México (UNAM), Facultad de Estudios Superiores (FES) Iztacala, Biomedicine Research Unit (UBIMED), Lung Diseases And Cancer Epigenomics Laboratory, Mexico State, Mexico 2Instituto Mexicano del Seguro Social (IMSS), Centro Medico Nacional (CMN) Siglo XXI, Unidad de Investigación Médica en Enfermedades Oncológicas (UIMEO), Molecular Oncology Laboratory, Mexico City, Mexico 3National Cancer Institute (INCAN), Thoracic Oncology Clinic, Mexico City, Mexico 4National Institute of Respiratory Diseases (INER), Ismael Cosío Villegas, Mexico City, Mexico 5Harvard Medical School, Harvard School of Public Health, Department of Environmental Health, Boston Massachusetts, USA Correspondence to: Federico Ávila Moreno, email:
[email protected],
[email protected] Keywords: lung cancer, homeobox transcription factors, Epigenetics cancer drug resistance, overall survival, treatment prognosis Received: May 26, 2016 Accepted: April 11, 2017 Published: May 09, 2017 Copyright: Leonel et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC-BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Several homeobox-related gene (HOX) transcription factors such as mesenchyme HOX-2 (MEOX2) have previously been associated with cancer drug resistance, malignant progression and/or clinical prognostic responses in lung cancer patients; however, the mechanisms involved in these responses have yet to be elucidated.